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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. AD pathology is characterized by abnormal aggregation
of the proteins amyloid-𝛽 (A𝛽) and hyperphosphorylated tau. No effective disease modifying therapies are currently available. A
short-duration intervention with 40 Hz light flicker has been shown to reduce brain A𝛽 load in transgenic mice. We aimed to
test the effect of a similar short-duration 40 Hz light flicker regime in human AD patients. We utilized a Light Emitting Diode
(LED) light bulb with a 40 Hz flicker. Six A𝛽 positive patients received 10 days of light therapy, had 2 hours of daily exposure, and
underwent a postintervention PiB PET on day 11. After 10 days of light therapy, no significant decrease of PiB SUVR values was
detected in any volumes of interest tested (primary visual cortex, visual association cortex, lateral parietal cortex, precuneus, and
posterior cingulate) or in the total motor cortex, and longer treatments may be necessary to induce amyloid removal in humans.
1. Introduction
Alzheimer’s disease (AD) pathology is characterized by ab-
normal aggregation of the proteins amyloid-𝛽 (A𝛽) and hy-
perphosphorylated tau accompanied by brain inflammation
in the form of microglial activation [1, 2]. No effective
disease-modifying therapies are currently available for AD.
To date, immunotherapy trials, with both passive antiamyloid
and antitau antibodies and vaccines, while proving effective
in lowering the abnormally aggregated protein load, have
generally proved ineffective in improving cognitive status
with one possible exception (aducanumab) though further
trials are currently running inmild cognitive impairment and
amyloid positive elderly subjects without cognitive symptoms
[3, 4].
A recent animal study demonstrated a 50% decline in
insoluble A𝛽 load in the cortex of an AD transgenic mouse
model after a 1-hour exposure to 40 Hz noninvasive light
stimulation each day for 7 days [5]. This is the first evidence
that the induction of 40 Hz gamma frequencies enhances
clearance of pathological protein inclusion in an AD model
though, interestingly, higher and lower frequencies proved
ineffective. Positron emission tomography (PET) radiotrac-
ers are now available to image in vivo aggregated A𝛽, in-
cluding 11C-Pittsburgh compound B (PiB) [6].
It is interesting andbreaking knowledge if the results from
the mouse studies can be replicated in humans as the theory
behind AD is based on A𝛽 and microglial activation [7, 8].
Iaccaroni et al. showed that microglia were activated by light
therapy reduced the A𝛽 load.
We have performed a pilot studywith the specific hypoth-
esis that daily exposure to short-duration 40 Hz light flicker
stimulation would diminish the cortical A𝛽 load in AD and
MCI subjects with abnormal PiB PET scans and, if it does,
further studies are needed to explain themechanisms behind.
2. Methods
2.1. Subjects. Five mild-to-moderate AD patients and one
mild cognitive impairment (MCI) patient were recruited
to the study. All subjects received their diagnoses from
Dementia Clinics inDenmark in accordancewith ICD-10AD
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and Petersen MCI criteria [9]. All subjects were in treatment
with donepezil.
Further inclusion criteria were as follows: (1) age: 50-85
years; (2) ≥7 years of education or working history. Exclusion
criteria were as follows: (1) past history of concussive head
injury or stroke; (2) previous history of epilepsy or current
epilepsy; (3) current migraine; (4) contraindications to MRI;
(5) significant systemic or psychiatric diseases; (6) other
neurodegenerative disease; (7) use ofmedications/treatments
which could influence neuropsychological testing, including
electroconvulsive therapy; (8) participation in other clinical
trials within 30 days of study entry.
2.2. Light Stimulus. We utilized a Light Emitting Diode
(LED) 40 Hz light bulb (12.5 ms light on, 12.5 ms light off).
The sharp on-off square-wave frequency flickering pattern
was verified with an oscilloscope (Supplementary Figure 1A).
Light flicker stimulation was tested one meter from a healthy
42-year-old male volunteer fitted with an EEG electrode
montage (SOMNOMedics, Randersacker, Germany). A photic
driving response was confirmed, i.e., presence of 40 Hz
oscillations in frontal and occipital leads (Supplementary
Figure 1B). Light stimulationwas performedwith the patients
seated in their own home in the dark. The background
illumination was measured to be 0.5-0.6 LUX at the locations
where patients received light stimulation. Thus, maximal
light-dark contrast was ensured for the light flicker stim-
ulation. The light bulbs’ illumination was measured before
and after light therapy using a ISO-TECH ILM 1335 (ISO-
TECH, Midrand, South Africa) and was found to be stable
with no significant loss of efficiency, and mean intensity
measurements of the light sources were pretreatment Lux
=1815 ± 94.6 and posttreatment Lux= 1737 ± 68.3.
Caregivers were instructed to ensure that patients
received a continuous 60-minute 40 Hz light stimulation
twice daily (1 hour morning, 1 hour evening) for 10 consec-
utive days. No other light sources were allowed during treat-
ment (computer, tablet, mobile phone, television, etc.) but
the patients were allowed to read or do other manual chores
at a distance of 0.5-1 meter from the LED light source.
The patients were also asked to look directly into the light
source for a minimum of 5 minutes during every session.
Patients and caregivers were provided with a stopwatch and
instructed to record the total time duration of each light
session and the time spent looking directly at the light source.
Postintervention PiB scans were for all subjects performed
the day following the final intervention day.
2.3. Imaging. Isometric 1 mm T
1
-weighted magnetic reso-
nance imaging (MRI) was performed with a Skyra 3T system
(Siemens, Erlangen, Germany).
11C-PiB PET was performed with a High Resolution
Research Tomograph (ECAT HRRT, CTI/Siemens, Knoxville,
TN) according to a previously published scan protocol [1].
The pretreatment scans were performed at different time
before treatment start, while the posttreatment scans all
were performed on the day following the end of the light-
therapy, i.e., on day 11. A mean dose of 407 ± 13.8 MBq
(for poststimulation scans) and 424 ± 15.3 MBq (for the
prestimulation scans) 11C-PiB was injected, and list-mode
PET was acquired for 40-90 minutes postinjection. Data was
subsequently rebinned into five frames of 10 min each.
2.4. Image Analysis. The PNEURO toolbox from PMOD
version 3.6 (PMOD, Zu¨rich, Switzerland) was used for image
processing and analysis. MRI volumes were segmented into
grey matter (GM), white matter (WM), and cerebrospinal
fluid (CSF). GM masks were convolved with a probabilistic
atlas [10] to individualize VOIs to individual GM. Volumes
defining primary visual cortex and precuneus were manually
added to the atlas. Mean 50-90 min PiB images were coregis-
tered to individual anatomical MRI, and the transformation
matrices from the individual’s native MRI space to MNI
space were applied to the PET images. PiB SUVR images
were generated by dividing each voxel value in the averaged
PiB images by the mean PiB uptake in the individual’s
cerebellar GM VOI [11]. PiB SUVR values were sampled
from 5 VOIs: primary visual cortex, visual association cortex,
lateral parietal, precuneus, and posterior cingulate cortices.
To minimize spill-in/spill-out, no smoothing was applied
prior to extraction of PiB SUVR values from the VOIs.
Correct placement of each VOI in each subject was visually
confirmed on both MRI and PET in atlas space.
2.5. Statistical Analysis. Data is presented asmean± standard
deviation (SD). Data were analysed using STATA version 14.2
(StataCorp LP, Texas, USA). Paired t-tests were used to test
pre-/postchanges in PiB SUVRs with a p<0.05 threshold for
statistical significance.
We assumed a maximal test-retest coefficient-of-variance
of cortical PiB uptake of 12 % [12, 13]. A power calculation
with alpha=0.05 showed that wewould be able to detect a 20%
decline in PIB retention with 90% power.
3. Results
Demographic, clinical, and individual regional SUVR data
are presented in Table 1. Median duration from the baseline
PET scan to the poststimulation scan was 89 days (range: 18-
283), while all poststimulation scans were performed one day
after end stimulation. The average time duration of the light
therapy sessions was 61.5 ± 4.8 minutes per session, during
which the patients looked directly at the light source for 39.3
± 21.5 minutes per session (range: 10-65 minutes).
No significant mean PiB SUVR differences were detected
in any of the five VOIs on comparing pre- and post-stimula-
tion PET (p > 0.48; Figure 1). Additionally, no difference was
seen in total cortical 11C-PiB uptake using a total cortical GM
VOI (pre-SUVR 2.314 ± 0.44; post-SUVR 2.378 ± 0.41; p =
0.7).
Figure 2 displays averaged pre- and poststimulation 11C-
PiB SUVR images of the six subjects. Concurrent negative
findings were found using the pons and WM as reference
regions (data not shown).
4. Discussion
This pilot study examined whether the marked 50% reduc-
tion of cortical A𝛽 seen in transgenic AD mice after
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Table 1: Demographic, clinical, and PET data.
Subject no. 1 2 3 4 5 6 Median [range]
Age (years) 70 67 73 54 85 80 71.5 [54-85]
Gender (F/M) F M M M M M (1/5)
CDR 1 0.5 0.5 0.5 0.5 0.5 0.5 [0.5; 1]
SOB 5.5 3.5 2 2.5 1.5 2.5 2.5 [1.5; 5.5]
MMSE 19 25 25 27 26 27 25.5 [19; 27]
AD/MCI AD AD MCI AD AD AD (5/1)
Disease dur. (months) 10 3 9 20 13 10 [3; 20]
Pre-post scan duration (month) 9.5 1.1 0.6 1.1 13.8 4.0 2.5 [0.6; 13.8]
PiB SUVR: Mean [95 % CI]
Visual pre 3.13 2.12 1.27 2.39 1.67 1.18 1.96 [1.18; 2.74]
Visual post 3.41 2.10 1.39 2.14 1.61 1.22 1.98 [1.15; 2.81]
Difference (%) 9.0 % -1.3 % 9.5 % -10.6 % -3.2 % 4.0 % 1.2 % [-7.0; 9.4]
Vis. Ass pre 2.83 2.10 1.45 2.07 1.89 1.34 1.94 [1.39; 2.51]
Vis. Ass post 3.21 1.99 1.58 1.84 1.92 1.35 1.98 [1.30; 2.66]
Difference (%) 13.4 % -5.0 % 9.2 % -11.4 % 1.7 % 1.1 % 1.5 % [-8.0; 11.0]
Parietal pre 2.73 2.80 2.38 2.94 2.54 1.74 2.49 [2.03; 2.95]
Parietal post 2.99 2.71 2.83 2.57 2.34 1.83 2.58 [2.16; 3.0]
Difference (%) 9.6 % -3.3 % 18.9 % -12.6 % -7.9 % 5.2 % 4.4 % [-7.1; 15.9]
Precuneus pre 3.31 3.19 2.26 3.44 2.59 2.10 2.81 [2.21; 3.41]
Precuneus post 3.58 2.95 2.72 2.96 2.83 2.19 2.87 [2.40; 3.34]
Difference (%) 8.1 % -7.5 % 20.0 % -13.8 % 9.1 % 4.4 % 3.4 % [-9.3; 16.2]
Post. Cing. Pre 3.25 3.26 2.41 3.61 2.56 1.95 2.84 [2.18; 3.50]
Post. Cing. Post 3.54 3.19 2.94 3.09 2.63 2.12 2.92 [2.40; 3.34]
Difference (%) 8.8 % -2.3 % 22.1 % -14.4 % 2.8 % 9.0 % 4.3 % [-8.6; 17.2]
Global pre 2.87 2.57 2.00 2.69 2.19 1.61
Global post 3.17 2.46 2.33 2.35 2.30 1.67
Difference (%) 10.6 % -4.1 % 16.5 % -12.5 5.4 % 4.1 %
CDR: Clinical Dementia Rating; SOB: CDR sum-of-boxes; MMSE: minimental state examination; AD: Alzheimer’s disease; MCI, mild cognitive impairment;
SUVR: standardized uptake value ratio; pre: before light stimulation; post: after light stimulation.
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Figure 1: Mean PiB SUVR differences in five cortical regions. No
significant difference in SUVR before and after light stimulation was
seen (Prim = primary visual, Vis = visual association, Par = Parietal
lobe, Cun = Cuneus, and Cing = posterior cingulate).
short-duration exposure to 40 Hz light stimulation would
translate into human AD patients. However, we saw no effect
Post-stimulationPre-stimulation
Figure 2: Average 11C-PiB SUVR images of the six subjects in the
pre- and poststimulation conditions. No significant differences were
seen anywhere in cortical regions.
of 40Hz light-therapy onA𝛽 load in the primary visual cortex
or any other region of early AD patients.
A test-retest study showed a mean difference in PiB-
uptake of 3-7 % in cortical regions within 20 days [13].
The greatest difference of 12.7 % was seen in the striatum
[13]. We based our power calculation on a 12 % test-retest
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variance of PiB PET scans [12, 13], yielding 90% power to
detect a 20% decline in SUVR. We believe the 20% estimate
was conservative, as another PiB PET study reported lower
regional test-retest difference within 20 days. Thus, if there
was an effect of 40Hz light stimulation onA𝛽 load it wasmost
likely less than 20% and not comparable to the 50% reduction
seen in AD mice.
It is possible that a longer-duration light therapy regime
could have had a measurable effect. It is also possible that a
therapeutic effect in humans can only be achieved by looking
directly into the light source and not only by being exposed to
a flashing environment, although the published mouse study
applied only the latter. A recent PiB PET study showed that
injections of the human monoclonal antibody aducanumab,
which targets aggregated A𝛽, significantly reduced cortical
PiB signal over 52 weeks [4]. At 26 weeks only 60-70% of the
full effect had been achieved. It is questionable whether the
effect of aducanumab would have been detectable after only
10 days of therapy. The same may hold true for 40 Hz light
stimulation.
The study had several limitations: the duration of light
stimulation was brief, but this limitation was by design.
Two subjects had a significant gap between the pre- and
postintervention scans (>3months), whichmay have blunted
statistical power. Nevertheless, it can be concluded that light-
therapy induced reductions in cortical amyloid load of the
magnitude seen in mouse models (>50%) do not occur in
human patients.
The gamma entrainment, in form of the EEG response to
the 40 Hz light flicker, was tested on a young healthy subject
but not tested on our elderly subjects. Future studies should
preferably test the gamma entrainment on each individual
test subject.
All our subjects, including the MCI subject, were treated
with acetylcholine esterase inhibitors (donepezil); we cannot
exclude an effect of donepezil on gamma entrainment,
although it seems unlikely that a treatment, which restores
cognitive functions, would have a negative effect on the brains
neurophysiological condition.
Our findings also highlight the difference between trans-
genic rodent models of AD and the human condition.
Although mice models are a promising tool for investigating
efficacy of anti-A𝛽 interventions, there are anatomical and
physiological differences between humans and rodents and
the interspecies differences in A𝛽 aggregation and toxicity
might explain the difference in efficacy of therapeutic inter-
ventions between rodents and human [14].
In summary, a short-duration 40 Hz light therapy regime
did not decrease cortical amyloid load in patients with early
Alzheimer’s disease. Future studies are needed to investigate
whether extended duration therapies could have beneficial
effects.
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